Standard Biotools (LAB) Net Cash Flow (2010 - 2026)

Standard Biotools (LAB) has reported Net Cash Flow for 17 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 42.99% year-over-year to $4.0 million in Q2 2026; TTM through Jun 2026 was $110.8 million, a 200.4% increase from a year earlier, with the FY2025 full-year figure at -$46.4 million, down 139.59% from the prior year.
• Net Cash Flow was $4.0 million for Q2 2026 at Standard Biotools, down from $144.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $235.9 million in Q1 2024 and troughed at -$62.5 million in Q3 2023.
• A 5-year average of $13.5 million and a median of -$3.5 million in 2022 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 1885.84% in 2023, down 350.3% in 2023.
• Over 5 years, Net Cash Flow stood at $20.8 million in 2022, then plunged by 235.52% to -$28.2 million in 2023, then tumbled by 52.06% to -$42.9 million in 2024, then soared by 79.91% to -$8.6 million in 2025, then surged by 145.98% to $4.0 million in 2026.
• The last three Net Cash Flow figures came in at $4.0 million (Q2 2026), $144.5 million (Q1 2026), and -$8.6 million (Q4 2025), per Business Quant data.